researchdrivelogo.jpg
Global Antibiotics Market to Exceed $58,798.1 Million at a CAGR of 4.0% from 2020 to 2027 – Exclusive Report [234 Pages] By Research Dive
June 14, 2021 08:50 ET | Research Dive
New York, USA, June 14, 2021 (GLOBE NEWSWIRE) -- As per a recent report examined by Research Dive, the global antibiotics market is expected to gather a revenue of $58,798.1 million by 2027, rising...
ResearchDriveLogo.jpg
Growing Cases of Infectious and Chronic Diseases Expected to Fast-track the Growth of the Global Antibiotics Market by the end of 2027 – Exclusive Report [234 Pages] by Research Dive
January 19, 2021 09:00 ET | Research Dive
New York, USA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- According to a report published by Research Dive, the global antibiotics market is expected to garner a revenue of $58,798.1 million and exhibit a...
gmi logo.jpg
Pneumonia Therapeutics Market to value USD 2.8 Bn by 2026: Global Market Insights, Inc.
June 23, 2020 04:00 ET | Global Market Insights, Inc
Selbyville, Delaware, June 23, 2020 (GLOBE NEWSWIRE) -- Global Market Insights, Inc. has recently added a new report on pneumonia therapeutics market which estimates the global market valuation...
LOGO JPG.jpg
Cempra Retains Morgan Stanley to Lead Review of Strategic Business Options
March 13, 2017 07:00 ET | Cempra, Inc.
CHAPEL HILL, N.C., March 13, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for the acute care and...
LOGO JPG.jpg
Cempra to Present at 29th Annual ROTH Conference
March 03, 2017 07:00 ET | Cempra, Inc.
CHAPEL HILL, N.C., March 03, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for the acute care and...
LOGO JPG.jpg
Cempra Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
February 28, 2017 06:45 ET | Cempra, Inc.
—Management to host webcast and conference call today at 8:45 a.m. ET— CHAPEL HILL, N.C., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company...
LOGO JPG.jpg
Cempra to Report Fourth Quarter and Full Year 2016 Financial Results
February 14, 2017 16:15 ET | Cempra, Inc.
CHAPEL HILL, N.C., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
LOGO JPG.jpg
CORRECTING and REPLACING -- Cempra to Present at Upcoming Investor Conferences
February 08, 2017 09:41 ET | Cempra, Inc.
CHAPEL HILL, N.C., Feb. 08, 2017 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Cempra, Inc. (Nasdaq:CEMP), the Leerink Partners conference should be noted...
LOGO JPG.jpg
Cempra to Present at Upcoming Investor Conferences
February 08, 2017 07:30 ET | Cempra, Inc.
CHAPEL HILL, N.C., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
LOGO JPG.jpg
Cempra to Present at J.P. Morgan Healthcare Conference
January 04, 2017 07:00 ET | Cempra, Inc.
CHAPEL HILL, N.C., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...